Egalet a/s is a specialty pharma company within pain management. Egalet develops a portfolio of opioid sustained release formulations for chronic pain management based on novel, proprietary erosion technology. The range of products is characterized by drug abuse resistance and avoidance of dose dumping in alcohol.

Abuse of prescription opioid formulations has accelerated in the last ten years in particular in the US and has now passed the illicit use of marijuana. One of four US high school seniors abuse these formulations on a daily basis and more than 13% of the US population above the age of 12 years have experience of misuse of these compounds. There is a great need to market drug abuse resistant opioid formulations to counteract this development.

Dose dumping in alcohol is a common phenomenon with opioids ultimately forcing the withdrawal of PALLADONE from the US market in 2005. Most opioid formulations in the US accordingly carry a black box warning to prevent this problem. There is a need to market opioid formulations that are not subject to interaction with alcohol to ensure patient safety and life quality.

Egalet a/s has developed three distinct, proprietary oral administration technologies addressing particular challenges like drug abuse mentioned above but also oral dosing of large amounts of API or dosing to infants  and geriatric patients. Egalet pursues the development of products in these technologies with pharmaceutical partners.